Verrica Pharmaceuticals

Verrica Pharmaceuticals company information, Employees & Contact Information

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring relief to patients, deliver peace of mind to parents and caregivers, and advance accessible therapies to prescribers and payers. We are focused on changing the narrative around skin diseases and making treatment a more efficient process for both physicians and patients. Headquartered in West Chester, Pennsylvania, Verrica was founded in 2013. We are led by a seasoned management team with extensive pharmaceutical industry experience ranging from drug development through commercialization and collectively launched more than 50 products.

Company Details

Employees
82
Founded
-
Address
44 West Gay Street,
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
West Chester, Pennsylvania
Looking for a particular Verrica Pharmaceuticals employee's phone or email?

Verrica Pharmaceuticals Questions

News

Verrica Pharmaceuticals Receives EMA Support for YCANTH® MAA Filing to Treat Molluscum Contagiosum in Europe - Quiver Quantitative

Verrica Pharmaceuticals Receives EMA Support for YCANTH® MAA Filing to Treat Molluscum Contagiosum in Europe Quiver Quantitative

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewswire

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire

Verrica (Nasdaq: VRCA) could file EU MAA for YCANTH as early as Q4 2026 after EMA feedback - Stock Titan

Verrica (Nasdaq: VRCA) could file EU MAA for YCANTH as early as Q4 2026 after EMA feedback Stock Titan

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results - Yahoo Finance

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results Yahoo Finance

Verrica Pharmaceuticals to Report Second Quarter 2025 - GlobeNewswire

Verrica Pharmaceuticals to Report Second Quarter 2025 GlobeNewswire

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 - Yahoo Finance

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 Yahoo Finance

12‑Week Immune Activation: Verrica Presents Phase 2 VP-315 Tumor Microenvironment Data at SITC - Stock Titan

12‑Week Immune Activation: Verrica Presents Phase 2 VP-315 Tumor Microenvironment Data at SITC Stock Titan

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference GlobeNewswire

Verrica Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Dermatology Pipeline - Stock Titan

Verrica Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Dermatology Pipeline Stock Titan

Verrica Pharmaceuticals Announces That Development Partner, - GlobeNewswire

Verrica Pharmaceuticals Announces That Development Partner, GlobeNewswire

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts - Yahoo Finance

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts Yahoo Finance

Dermatology Therapeutics Leader Verrica Pharmaceuticals to Showcase at Major H.C. Wainwright Conference - Stock Titan

Dermatology Therapeutics Leader Verrica Pharmaceuticals to Showcase at Major H.C. Wainwright Conference Stock Titan

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results - Yahoo Finance

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results Yahoo Finance

$10M Milestone Achievement: Verrica's Molluscum Drug YCANTH Receives Landmark Japan Approval via Torii - Stock Titan

$10M Milestone Achievement: Verrica's Molluscum Drug YCANTH Receives Landmark Japan Approval via Torii Stock Titan

Verrica Hits Record Quarter: YCANTH Sales Surge 32.8% as $8M Partnership Milestone Achieved - Stock Titan

Verrica Hits Record Quarter: YCANTH Sales Surge 32.8% as $8M Partnership Milestone Achieved Stock Titan

Verrica Secures $18M in Milestones as Phase 3 Wart Treatment Trial Targets Massive Untapped Market - Stock Titan

Verrica Secures $18M in Milestones as Phase 3 Wart Treatment Trial Targets Massive Untapped Market Stock Titan

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors - GlobeNewswire

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors GlobeNewswire

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization - GlobeNewswire

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization GlobeNewswire

VP-315 Demonstrates Positive Topline Results in Basal Cell Carcinoma - Dermatology Times

VP-315 Demonstrates Positive Topline Results in Basal Cell Carcinoma Dermatology Times

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors - citybiz

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors citybiz

Verrica Pharmaceuticals Reports Increased Demand for YCANTH with New Single Applicator Configuration Coming in 2025 - Quiver Quantitative

Verrica Pharmaceuticals Reports Increased Demand for YCANTH with New Single Applicator Configuration Coming in 2025 Quiver Quantitative

Verrica Announces Positive Preliminary Topline Results From Part 2 of Phase 2 Study of VP-315 for BCC - Dermatology Times

Verrica Announces Positive Preliminary Topline Results From Part 2 of Phase 2 Study of VP-315 for BCC Dermatology Times

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 - Stock Titan

Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 Stock Titan

Verrica Pharmaceuticals Announces Specialty Pharmacy - GlobeNewswire

Verrica Pharmaceuticals Announces Specialty Pharmacy GlobeNewswire

FDA Approves VP-102 for Molluscum Contagiosum - HCPLive

FDA Approves VP-102 for Molluscum Contagiosum HCPLive

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. - GlobeNewswire

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference - Yahoo Finance

Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference Yahoo Finance

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC - Yahoo Finance

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC Yahoo Finance

NDA Submitted for Topical Molluscum Contagiosum Therapy - Medical Professionals Reference

NDA Submitted for Topical Molluscum Contagiosum Therapy Medical Professionals Reference

Verrica Appoints Neetu Dhaliwal as Vice President of Business Development - GlobeNewswire

Verrica Appoints Neetu Dhaliwal as Vice President of Business Development GlobeNewswire

Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis - MarketBeat

Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis MarketBeat

VRCA Stock Price and Chart — NASDAQ:VRCA - TradingView

VRCA Stock Price and Chart — NASDAQ:VRCA TradingView

Top Verrica Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant